Sclerostin, a secreted protein encoded by the Sost gene, is produced by osteocytes and is inhibited by osteoblast differentiation and bone formation. Recently, a functional association between bone and fat tissue has been suggested, and a correlation between circulating sclerostin levels and lipid metabolism has been reported in humans. However, the effects of sclerostin on adipogenesis remain unexplored. In the present study, we examined the role of sclerostin in regulating adipocyte differentiation using 3T3-L1 preadipocytes. In these cells, sclerostin enhanced These results show that sclerostin upregulates adipocyte differentiation in 3T3-L1 cells, suggesting a possible role for the osteocyte-derived sclerostin as a regulator of fat metabolism and as a reciprocal regulator of bone and adipose tissues metabolism.
Introduction
The existence of reciprocal regulation between bone and energy metabolisms is demonstrated by recent several reports [Karsenty and Oury, 2012] . Adipocytes play critical roles in the maintenance of energy balance, and these cells store energy in the form of lipids and release fatty acids in response to metabolic signals or to energy insufficiency [Ali et al., 2013] . Adipocytes are also known as endocrine cells that secrete a number of adipocytokines [Kadowaki and Yamauchi, 2005] . Among them, two adipocyte-derived secreted molecules, adiponectin and leptin, which are specifically and highly expressed in the adipose tissue and abundantly secreted into the blood, are known to regulate bone mass, and bone could be a target tissue for these hormones [Kajimura et al., 2013; Takeda et al., 2002] . In contrast, bone-derived molecules, which regulate adipocytes, have not been investigated yet. It was only reported that the osteoblast-specific secreted molecule osteocalcin behaves as a hormone regulating glucose metabolism and fat mass in mutant mice [DiGirolamo et al., 2012; Ferron et al., 2008] . However, it remains to elucidate which molecules secreted by bone cells can affect fat metabolism.
Sclerostin (the Sost gene product) is a 29 kDa secreted protein of 213 amino acids characterized as a negative regulator of bone formation [Baron and Kneissel, 2013; Ke et al., 2012; van Bezooijen et al., 2005] . In the adult bone, Sost is constitutively expressed by osteocytes, final differentiated cells of the osteoblast lineage [Burgers and Williams, 2013; van Bezooijen et al., 2005] . Their role was first appreciated when excessive bone mass was observed in patients with sclerosteosis or Van Buchem's disease, an autosomal recessive disease with mutations or deletions in the Sost gene [Balemans et al., 2001] . Furthermore, a high bone mass phenotype was observed in sclerostin-null mice [Li et al., 2008] and a low bone mass phenotype in sclerostin-overexpressing mice [Kramer et al., 2010] . Sclerostin was detectable in 4 serum in all healthy human subjects studied, suggesting that the protein is secreted and enters the circulation. From several data on circulating sclerostin serum levels in humans, a positive correlation was reported between circulating sclerostin and the percentages of abdominal fat, gynoid fat, and fat mass [Amrein et al., 2012; Klangjareonchai et al., 2014; Urano et al., 2012] . Consequently, it was suggested that sclerostin regulates adipogenesis or fat production. To date, little is known on the regulation of adipocyte differentiation in response to sclerostin.
During adipocyte differentiation, committed preadipocytes undergo growth arrest and subsequent terminal differentiation into adipocytes. In 3T3-L1 preadipocytes, growth-arrested cells have been shown to re-enter the cell cycle synchronously and to undergo mitotic clonal expansion in response to differentiation inducer treatment (a combination of 3-isobutyl-1-methylxanthine; [IBMX] , dexamethasone, and insulin), before exiting the cell cycle and terminally differentiating [MacDougald and Lane, 1995] .
Many transcription factors act sequentially during the differentiation processes [Rosen and Spiegelman, 2000] . Among them, CCAAT/enhancer binding protein (C/EBP) β is a key transcription factor transcribed, phosphorylated, and activated immediately after exposure to the differentiation inducer treatment, thus resulting in the transactivation of C/EBPα and peroxisome proliferator-activated receptor (PPAR) γ [Guo et al., 2015] . C/EBPα and PPARγ can initiate differentiation, and acquisition of the adipocyte phenotype is characterized by an increase in the expression of adipocyte-specific genes such as lipoprotein lipase (LPL) [Rosen and Spiegelman, 2000] . Several hormones and growth factors that affect adipocyte differentiation in a positive or negative manner have been identified. Growth hormone and insulin like growth factor 1 stimulates adipogenesis. In contrast, the epidermal growth factor, transforming growth factor (TGF)-α, TGF-β, and retinoic acid are generally considered inhibitors of adipocyte differentiation [Rosen and Spiegelman, 2000] . Also, canonical Wnt ligands are known to 5 inhibit differentiation [Ross et al., 2000] .
The effects of Wnt ligands on the canonical signaling pathway involving β-catenin are mediated by their binding to the Frizzled receptor and to coreceptors, low-density lipoprotein receptor-related proteins (LRPs) 4/5/6 [MacDonald et al., 2009 ].
Sclerostin was reported as an antagonist of the canonical Wnt signaling pathway by binding to the extracellular domain of LRP4/5/6 and disrupting Wnt-induced Frizzled-LRP complex formation [Baron and Kneissel, 2013; Li et al., 2005] . Canonical Wnt signaling causes stabilization of β-catenin, which then translocates into the nucleus, where it interacts with transcription factors including the lymphoid enhancing factor 1 and T-cell factors (TCFs) that regulate the expression of several target genes [MacDonald et al., 2009] . TAZ is a transcriptional coactivator originally identified in a proteomic screening for 14-3-3 binding protein [Kanai et al., 2000] and is well known to be regulated by the Hippo signaling pathway . Recently, Azzolin et al. [Azzolin et al., 2012] reported TAZ as a downstream component of the canonical Wnt signaling pathway and as a mediator of Wnt biological responses independent of the Hippo pathway. It has been proposed that the canonical Wnt pathway induces TAZ protein stabilization and transcriptional activity in multiple cell types [Azzolin et al., 2014; Azzolin et al., 2012] .
In the present study, we investigated whether osteocyte sclerostin regulates adipocyte differentiation. We found that sclerostin enhances adipocyte differentiation in 3T3-L1 cells and reduced TAZ-responsive transcriptional activity and TAZ-responsive gene expression, indicating a role for TAZ as a regulator of adipogenesis by sclerostin.
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Materials and Methods
Reagents
IBMX and dexamethasone were purchased from Sigma-Aldrich (St. Louis, MO). Insulin was purchased from Cell Science and Technology Institute Inc. (Sendai, Japan).
Recombinant mouse sclerostin and Wnt3a were purchased from R&D Systems (Minneapolis, MN).
Cell cultures
3T3-L1 cells were obtained from the DS Pharma Biomedical Inc. (Osaka, Japan) and grown to confluence in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) with 100 μg/mL of kanamycin (Meiji, Tokyo, Japan) and 10% fetal bovine serum (FBS; SAFC Bioscience, Inc., Lenexa, KS) at 37 o C in a humidified atmosphere of 5% CO2. For adipocyte differentiation, at two days postconfluence (day 0), differentiation was induced using the differentiation inducer treatment (500 μM IBMX, 10 μg/mL insulin and 1 μM dexamethasone) added to a basal medium. At day 3, the medium was replaced with adipogenic medium containing DMEM supplemented with 10% FBS and 10 µg/ mL insulin, which was changed every two days thereafter until analysis.
Oil red O staining
3T3-L1 cells were washed with phosphate-buffered saline (PBS) and fixed with 10% formalin for one hour at room temperature. The cells were then rinsed with 60% isopropanol. Oil red O (0.12%, Sigma-Aldrich) was added and incubated for 10 min with gentle agitation, followed by further washing with PBS. The dishes were subsequently scanned to get the pictures. Quantification of oil red O staining was performed by eluting the stain from the cells using 100% isopropanol and then quantifying the absorbance (520 nm) of the staining against a blank (100% isopropanol) on a spectrophotometer 7 (Hitachi U-1500, Tokyo, Japan).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the cells using Isogen (Nippongene, Toyama, Japan) as described previously [Nakashima et al., 2005] . RT-PCR was performed as previously described [Nakashima et al., 2005] . The primer sequences for each gene are shown in the Table. To account for any difference in the amount of RNA, β-actin was chosen as the endogenous control. The amplification products were separated by electrophoresis on 2% agarose gels.
Quantification of gene expression by quantitative RT-PCR (qRT-PCR)
The qRT-PCR was performed using assay-on-demand TaqMan probes (Applied Biosystems, Foster City, CA) and the StepOne ® real time PCR system according to the manufacturer's protocol as previously described [Iizuka et al., 2014] . The relative level of gene expression was quantified using the comparative CT method with β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression as the endogenous control.
Transfection of small interfering RNA (siRNA)
3T3-L1 cells were transfected with Silencer select predisigned siRNA for the TAZ (Ambion, ID number s97145) gene or with Silencer negative control siRNA #1 (Ambion) at a concentration of 10 nM using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions as described previously [Uyama et al., 2012] . 
Western blot analysis
Reporter constructs and assay for luciferase activity
The 8xGTIIC-Lux luciferase reporter construct [Dupont et al., 2011] , a synthetic luciferase sensor containing multimerized responsive elements of TEAD, the main DNA-binding cofactor of TAZ, was obtained from Addgene (34615; Cambridge, MA).
The reporter assay was performed as described previously [Nakashima et al., 2005] .
Detection of DNA synthesis by chemiluminescent bromodeoxyuridine (BrdU)
ELISA
To measure cell proliferation, newly synthesized DNA of replicating cells was assayed by BrdU incorporation using a BrdU labeling and detection ELISA-kit (Cell Proliferation Biotrak ELISA System version 2, GE Healthcare) according to the manufacturer's instructions. Briefly, confluent 3T3-L1 cells were incubated in differentiation media and treated with sclerostin, and then cultured for further 24 h. Then, BrdU was added to the cells. After 4 h, cells were fixed and DNA denatured, then incubated with an antibody to BrdU conjugated with peroxidase (60 min, 37°C). Immune complexes were detected by incubation with tetramethylbenzidine as substrate for 5 min, the reaction was stopped with H2SO4 and absorption measured at 450 nm using a microplate reader (iMark, 9 Bio-Rad).
Measurement of caspase-3/7 activity
Cellular enzymatic activities of caspase-3/7 were determined by a caspase colorimetric assay (Caspase-Glo 3/7 Assay Systems, Promega, Madison, MI) as described previously [Iizuka et al., 2014] . Briefly, for each reaction, cells were lysed and incubated with a luminogenic substrate containing the DEVD sequence, which is cleaved by activated caspase-3/7. After incubation at room temperature for one hour, luminescence was quantified using a Mini Lumat LB 9506 luminometer (Berthold, Bad Wildbad, Germany).
Generation of plasmid construct and over-expression of TAZ
TAZ expression plasmid was generated as follows and designated as pTAZ. Mouse TAZ cDNA was amplified from 3T3-L1 cells cDNA using primers designed to flank the mouse TAZ open reading frame (forward 5'-GGTTCCAGCTCGTCAGTT-3', reverse 5'-GTGTGAGTACAAAGGCAG-3') using PrimeSTAR Max DNA polymerase (Clontech Laboratories, Inc. Mountain View, CA) according to the manufacturer's instructions. The PCR product was run on a 1% agarose gel, purified and subcloned into the pcDNA3 vector (Invitrogen) using the In-Fusion advantage PCR cloning kit (Clontech) by KpnI and XbaI sites according to the manufacturer's instructions. Individual clones of transformed E.coli were isolated from agar plates and the nucleotide sequences of each plasmid were confirmed by DNA sequencing. 3T3-L1 cells were transfected with pTAZ or empty vector (pcDNA3) using ScreenFect A (Wako Pure Chemical Industries Ltd., Osaka, Japan) according to the manufacturer's instructions.
Statistical analysis
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The data are reported as the mean ± standard deviation of three independent experiments and were analyzed by Student's t-test; values of P < 0.05 were considered significant.
Results
Sclerostin positively regulates adipocyte differentiation in 3T3-L1 cells
To evaluate a potential role for sclerostin on adipocyte differentiation, we used Fig. 2A) , as previously reported [Bennett et al., 2002; Ross et al., 2000] . Addition of sclerostin attenuated the Wnt3a-dependent reduction of adiponectin and PPARγ mRNA expression ( Fig. 2A) . As expected, Wnt3a decreased the amount of oil red O staining to a comparable degree of the staining in cells differentiated in the presence of differentiation media alone. Wnt3a-mediated reduction of oil red O staining was increased by the addition of sclerostin (Fig. 2B) , indicating that sclerostin attenuated the effect of canonical Wnt on 3T3-L1 cell differentiation.
Sclerostin has been reported to interfere with the canonical Wnt signaling pathway due to binding to the Wnt coreceptors LRP5/6 [Li et al., 2005] and LRP4 [Holdsworth et al., 2012] . Therefore, we examined which LRP may be expressed by 3T3-L1 cells. LRP5 and 6 mRNAs were detected in 3T3-L1 cells, whereas LRP4 mRNA expression could not be detected in these cells (Fig. 2C) . Osteoblastic MC3T3-E1 cells expressed LRP4, 5, and 6 (Fig. 2C) , as previously reported elsewhere [Choi et al., 2009] .
Sclerostin regulates C/EBPβ expression but not cell proliferation and caspase-3/7 activity in 3T3-L1 cells
The differentiation of 3T3-L1 cells into adipocytes is accompanied by a transient induction of C/EBPβ, and overexpression of C/EBPβ has been shown to induce adipocyte differentiation [Guo et al., 2015] . Therefore, C/EBPβ expression was examined in response to sclerostin treatment. Sclerostin increased C/EBPβ protein level 24 hours after differentiation inducer treatment (Fig. 3A) . However, DNA synthesis and caspase-3/7 activity were not altered by sclerostin treatment in 3T3-L1 cells (Figs.
3B and 3C), indicating that the enhancement of adipocyte differentiation by sclerostin was not dependent on cell proliferation and apoptosis.
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Regulation of TAZ activity by sclerostin
Recently, canonical Wnt signaling has been reported to regulate direct transcriptional activation of responsive elements of TEAD, the main DNA-binding cofactor of the transcriptional coactivator TAZ [Azzolin et al., 2012] . Therefore, to explore the effect of sclerostin on this transcriptional activity, we transfected 3T3-L1 cells with 8xGTIIC-Lux [Dupont et al., 2011] , a synthetic luciferase reporter containing multimerized responsive elements of TEAD. The induction of luciferase activity was observed after the treatment with Wnt3a, and sclerostin reduced the activity induced by Wnt3a (Fig. 4A) . Sclerostin reduced the luciferase activity (Fig. 4A) . Next, we examined the expression of the TAZ target gene ctgf ] in 3T3-L1 cells. Ctgf mRNA expression was induced by Wnt3a, whereas sclerostin inhibited Wnt3a-induced or not-induced ctgf expression (Fig. 4B) . These results indicated that sclerostin downregulated TAZ activity in 3T3-L1 cells.
Effects of TAZ knockdown or over-expression on sclerostin-mediated adipocyte differentiation in 3T3-L1 cells
To evaluate the potential biological relevance of regulation of the TAZ pathway in sclerostin-mediated adipocyte differentiation, we examined the effect of TAZ knockdown using RNA interference. Following transfection of 3T3-L1 cells with TAZ siRNA, the protein level of TAZ diminished, confirming that the siRNA was effective in silencing endogenous TAZ expression (Fig. 4C) . The increase of lipid accumulation was observed in TAZ siRNA-treated cells compared with control siRNA-treated 3T3-L1 cells (Fig. 4D) , indicating that knockdown of TAZ induces adipocyte differentiation. and 5D). These results indicate that adipocyte differentiation is TAZ dependent and that sclerostin may be involved in regulating adipocyte differentiation via TAZ.
Discussion
In this study, osteocyte-produced sclerostin enhances adipocyte differentiation in 3T3-L1 preadipocytes. Adipose tissue mass is determined by the increase in adipocyte size and number [Ali et al., 2013] . The size of adipocytes augments because of increased storage of triacylglycerols from dietary sources or endogenous lipogenesis.
On the other hand, adipocyte number increases as a result of enhanced cell proliferation and differentiation [Ali et al., 2013] . Evidence from several in vivo studies supports the idea that sclerostin regulates adipose tissue. For example, it has been shown that serum circulating sclerostin is related to fat metabolism and adiposity [Amrein et al., 2012; Colaianni et al., 2014; Urano et al., 2012] . Recently, Ma et al.
reported a cross-sectional cohort study showing that serum sclerostin was positively associated with total fat mass . Adipocyte differentiation therefore requires the cells to process a variety of combinatorial inputs during differentiation induction. Identification of various molecules that modulate the process in either a positive or negative manner provides insight into the fat metabolism regulation in the adipose tissue [Ali et al., 2013] . With our study we provide a molecular novel role for osteocyte-produced sclerostin in metabolism control between adipose tissue and bone tissue. We speculate that osteocyte lacunocanalicular network can function as an endocrine system to secrete sclerostin into blood targeting distant organs. To date, there are few reports on the regulation of sclerostin expression in osteocytes and on its entry into the circulation. Since adipose tissue produces a variety of secretory factors that exert effects at the systemic level, such factors may regulate sclerostin production and secretion from the bone tissue.
During adipocyte differentiation, sclerostin may act via specific receptors to transduce external growth and differentiation signals through a cascade of intracellular events. Sclerostin binds to LRP5/6, and point mutations in the amino-terminal 16 β-propeller domain of LRP5, which are associated with high bone mass, reduce the ability of sclerostin to interact with LRP5 [Semënov et al., 2005; Semenov and He, 2006] , suggesting that sclerostin interacts with the amino-terminal region of LRP5/6, thus mediating biological functions. Sclerostin has also been shown to bind to another member of the LDL receptor family, LRP4 [Choi et al., 2009] , and different regions of sclerostin interact with LRP5/6 and LRP4 [Holdsworth et al., 2012] . LRP4/5/6 are widely and constitutively expressed in several types of peripheral tissues including osteoblasts [He et al., 2004] . A rare mutation in LRP6 was found to be associated with a metabolic syndrome and with diabetes [Mani et al., 2007; Singh et al., 2013] . LRP6 +/-mice on a high fat diet were protected against diet-induced obesity and adipose tissue insulin resistance compared with their wild-type littermates, suggesting that LRP6 regulates genes involved in adipogenesis, metabolism and insulin signaling [Liu et al., 2012] . Our study shows that 3T3-L1 preadopocytes express detectable levels of LRP5/6 but not of LRP4, suggesting that sclerostin acts via LRP5/6 to transduce signals through a cascade of intracellular events during adipocyte differentiation. Since LRP6 has been shown to regulate body weight and glucose metabolism as a nutrient sensing factor, we think that sclerostin may have a role in nutrient sensing. Although, since LRP dominant function during adipocyte differentiation regulated by sclerostin is unknown, our observation supports the idea that LRP5/6 is predominantly expressed by preadipogenic cells and mediates adipocyte differentiation interacting with sclerostin in the adipose tissue.
Sclerostin is known as an inhibitor of the canonical Wnt signaling pathway.
Signaling ligands such as Wnt1 or Wnt10b suppress adipocyte differentiation [Bennett et al., 2002; Ross et al., 2000] . Based on our observation, not only sclerostin but also the small molecular inhibitors IWR-1 may block the activation of canonical Wnt signaling pathway [Chen et al., 2009] induced by adipocyte differentiation in 3T3-L1 cells (data 17 not shown). Consistent with our studies, it has been shown that dominant-negative TCF4 or another soluble inhibitor of Wnt signaling, such as the secreted frizzled related protein, induces adipocyte differentiation [Bennett et al., 2002; Ross et al., 2000] . Taken together, our results suggest that sclerostin may inhibit endogenous canonical Wnt signaling and then enhance adipocyte differentiation. Another possibility is that sclerostin itself may interact with specific receptors and induce certain intracellular signaling, resulting in 3T3-L1 adipocyte differentiation. With this work we have uncovered a precise molecular mechanism by which sclerostin may function as an inducer of adipocyte differentiation.
During 3T3-L1 adipocyte differentiation, C/EBPβ is induced early and plays a crucial role [Guo et al., 2015] . Upon the treatment with differentiation inducer, growth-arrested 3T3-L1 cells re-enter the cell cycle, a process referred to as mitotic clonal expansion (MCE) characterized by impaired proliferation, which contributes to adipocyte hyperplasia. The adipogenic gene expression program is initiated during and after MCE, ultimately leading to terminal adipocyte differentiation [Guo et al., 2015] .
Several lines of evidence have shown that C/EBPβ is involved during MCE. Enhanced expression of C/EBPβ by sclerostin-as shown by our results-may contribute to MCE, resulting in the enhancement of 3T3-L1 adipocyte differentiation.
TAZ, a transcriptional modulator, has a key role in cell proliferation, differentiation, and stem cell self-renewal. TAZ activity is regulated by several signaling pathways, including Hippo and canonical Wnt signaling . In this study, we show that sclerostin inactivates the TAZ responsive luciferase reporter containing responsive elements TEAD, which is induced by Wnt3a. Recently, Byun et al.
[ Byun et al., 2014] reported that Wnt3a facilitates the dephosphorylation of TAZ, stabilizing TAZ and preventing its binding to 14-3-3 proteins, thus inducing nuclear localization of TAZ. Our analysis implies the presence of a transcriptional machinery 18 that is sensitive to sclerostin, that regulates TAZ activity, and that modulates transcriptional activity through interaction with the TAZ-responsive gene promoter (i.e., ctgf gene) . Recently, in human clinical studies, the administration of sclerostin-neutralizing monoclonal antibodies has shown that pharmacologic inhibition of sclerostin results in increased bone formation, bone mass, and bone strength [McClung et al., 2014] . Sclerostin upregulates adipocyte differentiation, suggesting that an anti-sclerostin neutralizing antibody might act as a potent TAZ activator and could be an anabolic agent to be used therapeutically to prevent or reverse fat gain in conditions such as metabolic diseases.
In conclusion, we have shown that sclerostin regulates adipocyte differentiation.
This is the first molecular study linking the osteocyte-derived molecule sclerostin to adipocytes. Further investigations may provide important new information pertaining to the molecular basis of the cross-regulation of metabolism between bone and fat tissues. were treated with sclerostin (20 ng/mL), Wnt3a (10 ng/mL), sclerostin (20 ng/mL) and Wnt3a (10 ng/mL) or vehicle (-) for 6 h, after which luciferase activity was determined.
Normalized luciferase activity is shown as the ratio of luciferase activity relative to 
